Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL733832 | 0.64 | — | — | |
| SCHEMBL887787 | 0.62 | TDP1 (0.38) | TSHR | |
| SCHEMBL30898370 | 0.62 | TSHR (0.35) | TSHR | |
| SCHEMBL264243 | 0.60 | — | — | |
| SCHEMBL4741885 | 0.58 | — | — | |
| SCHEMBL6590316 | 0.58 | — | — | |
| SCHEMBL104305 | 0.58 | — | — | |
| SCHEMBL27623259 | 0.58 | — | — | |
| SCHEMBL1060663 | 0.57 | TSHR (0.30) | TSHR | |
| SCHEMBL8725917 | 0.57 | LMNA (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024175087-A1 | OLIGONUCLEOTIDE TARGETING SOD1 | RACTIGEN THERAPEUTICS (CN) | 2024-08-29 | — | — | WO | claimed |
| WO-2024175087-A1 | OLIGONUCLEOTIDE TARGETING SOD1 | RACTIGEN THERAPEUTICS (CN) | 2024-08-29 | — | — | WO | disclosed |
| EP-4288542-A1 | MULTI-VALENT OLIGONUCLEOTIDE AGENT AND METHODS OF USE THEREOF | Ractigen Therapeutics (CN) | 2023-12-13 | — | — | EP | disclosed |
| WO-2022166849-A1 | MULTI-VALENT OLIGONUCLEOTIDE AGENT AND METHODS OF USE THEREOF | RACTIGEN THERAPEUTICS (CN) | 2022-08-11 | — | — | WO | disclosed |
| US-8057997-B2 | Nucleic acid binding compounds containing pyrazolo[3,4-D]pyrimidine analogues of purin-2,6-diamine and their uses | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20110021365-A1 | Nucleic Acid Binding Compounds Containing Pyrazolo[3,4-D]Pyrimidine Analogues of Purin-2,6-Diamine and Their Uses | ROCHE MOLECULAR SYSTEMS, INC. | 2011-01-27 | — | — | US | disclosed |
| US-7238795-B2 | Nucleic acid binding compounds containing pyrazolo[3,4-d]pyrimidine analogues of purin-2,6-diamine and their uses | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1071764-B1 | ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF INTEGRIN ALPHAV-SUBUNIT EXPRESSION | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-07-12 | — | — | EP | disclosed |
| US-6667299-B1 | 16-alpha-bromo-3-beta-hydroxy-5-alpha-androstan-17-one hemihydrate; 16-alpha-bromoepiandrosterone; steroid; immune modulator | HOLLIS-EDEN PHARMACEUTICALS, INC. | 2003-12-23 | — | — | US | disclosed |
| US-20030198982-A1 | Nucleic acid binding compounds containing pyrazolo[3,4-d]pyrimidine analogues of purin-2,6-diamine and their uses | ROCHE MOLECULAR SYSTEMS, INC. | 2003-10-23 | — | — | US | disclosed |
| EP-1100894-A2 | SHORT OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION | Aventis Pharma Deutschland GmbH (DE) | 2001-05-23 | — | — | EP | disclosed |
| WO-2001007602-A2 | OLIGONUCLEOTIDES FOR INHIBITING THE EXPRESSION OF HUMAN EG5 | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-02-01 | — | — | WO | disclosed |
| EP-1071764-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF INTEGRIN $g(a) v?-SUBUNIT EXPRESSION | Aventis Pharma Deutschland GmbH (DE) | 2001-01-31 | — | — | EP | disclosed |
| US-6033909-A | INHIBITORS OF GENE EXPRESSION | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-03-07 | — | — | US | disclosed |
| WO-2000008140-A2 | ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-02-17 | — | — | WO | disclosed |
| WO-2000008141-A2 | SHORT OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-02-17 | — | — | WO | disclosed |
| EP-0979869-A1 | Short oligonucleotides for the inhibition of VEGF expression | Hoechst Marion Roussel Deutschland GmbH (DE) | 2000-02-16 | — | — | EP | disclosed |
| EP-0978561-A1 | Antisense oligonucleotides for the inhibition of VEGF expression | Hoechst Marion Roussel Deutschland GmbH (DE) | 2000-02-09 | — | — | EP | disclosed |
| WO-1999054456-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF INTEGRIN αv-SUBUNIT EXPRESSION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-10-28 | — | — | WO | disclosed |
| EP-0950709-A1 | Antisense oligonucleotides for the inhibition of integrin alphaV-subunit expression | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030198982-A1 | Nucleic acid binding compounds containing pyrazolo[3,4-d]pyrimidine analogues of purin-2,6-diamine and their uses | ADAR, NT5C3B, NT5C2 | TSHR 4040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.